Evaluation of the hepatotoxic potential of citalopram in rats

Authors : Sinem ILGIN, Fulya DAĞAŞAN, Dilek BURUKOĞLU DÖNMEZ, Merve BAYSAL, Özlem ATLI EKLİOĞLU

Pages : 188-194

View : 49 | Download : 11

Publication Date : 2020-12-30

Article Type : Research Paper

Abstract :Background and Aims: Citalopram is a selective serotonin reuptake inhibitor with a high potency which is occasionally prescribed and used to treat major depression associated with mood disorders as a first-line drug. According to the results of previous studies, evidence of hepatotoxicity related to citalopram treatment were limited and conflicting. Therefore, we aimed to evaluate the hepatotoxicity potential of sub-chronic citalopram administration. Methods: Citalopram was administered to female rats orally in 5 and 10 mg/kg for 30 days. After the exposure period, serum aspartate aminotransferase insert ignore into journalissuearticles values(AST);, alanine aminotransferase insert ignore into journalissuearticles values(ALT);, total and direct bilirubin levels as biomarkers of hepatotoxicity were measured and histopathological examination of liver tissues was performed. Additionally, GSH levels of liver tissues were determined. Results: The risk of hepatotoxicity related to citalopram was shown by significant increases of serum hepatic biomarkers, AST, ALT, and total bilirubin in citalopram-administered groups. According to the histopathological findings, hepatocellular necrosis, hepatic nuclear asymmetry, and disarrangement of hepatic cord cells insert ignore into journalissuearticles values(hepatocytes); were prominent in the 10 mg/kg citalopram- administered group. On the other hand, there was no significant difference among the groups in terms of GSH levels. Conclusion: The results suggested that the administration of citalopram might cause hepatotoxic effects, depending on the dose.
Keywords : Citalopram, hepatotoxicity, hepatic biomarker, liver histology, oxidative status

ORIGINAL ARTICLE URL